ContextVision AB (publ)

Oslo Stock Exchange CONTX.OL

ContextVision AB (publ) Price to Sales Ratio (P/S) on January 14, 2025: 2.78

ContextVision AB (publ) Price to Sales Ratio (P/S) is 2.78 on January 14, 2025, a -37.75% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • ContextVision AB (publ) 52-week high Price to Sales Ratio (P/S) is 5.08 on February 01, 2024, which is 82.75% above the current Price to Sales Ratio (P/S).
  • ContextVision AB (publ) 52-week low Price to Sales Ratio (P/S) is 2.52 on November 15, 2024, which is -9.48% below the current Price to Sales Ratio (P/S).
  • ContextVision AB (publ) average Price to Sales Ratio (P/S) for the last 52 weeks is 3.35.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Loading...
Oslo Stock Exchange: CONTX.OL

ContextVision AB (publ)

CEO Dr. Gerald Potzsch
IPO Date Jan. 3, 2000
Location Sweden
Headquarters HollAendargatan 13, 2 tr
Employees 41
Sector Technology
Industries
Description

ContextVision AB (publ), a medical technology software company, provides image analysis and artificial intelligence software solutions to original equipment manufacturers in Asia, Europe, and the United States. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and mammography. Its products include Rivent that offers unparalleled image quality for various types of ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; VolarView, an image enhancement software for the handheld ultrasound market segment; and GOPiCE, a technology for volumetric image enhancement in real-time. The company also provides Altumira/Altumira Plus, a platform for digital radiography; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI; and INIFY Prostate Screening for digital analysis of prostate biopsies. The company was founded in 1983 and is headquartered in Stockholm, Sweden.

Similar companies

KIT.OL

Kitron ASA

USD 3.12

-0.24%

CRAYN.OL

Crayon Group Holding ASA

USD 10.34

-0.58%

AZT.OL

ArcticZymes Technologies ASA

USD 1.20

-0.29%

STRO.OL

StrongPoint ASA

USD 0.98

-0.46%

StockViz Staff

January 15, 2025

Any question? Send us an email